Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer

NCT05413850 is registered in ClinicalTrials.gov with Blue Earth Therapeutics Ltd as lead sponsor.

NCT NCT05413850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05413850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer
Lead sponsor
Blue Earth Therapeutics Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 20, 2022
Completion date
March 31, 2028
Enrollment
82 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc, metastatic castration-resistant prostate cancer, prostate cancer, prostatic diseases, prostatic neoplasms, urogenital neoplasms